Accelrys NanoBiology Seminar Series ``Nanodesign: Revolutionizing Healthcare and Medicine through Nanotechnology'' Comes to Boston Area
|August 8 Meeting to Feature Leading Nanobiology Researchers Discussing Nanotechnology-based Pharmaceutical and Diagnostics Design|
“Our seminar in Boston is designed to provide attendees a deep technical and scientific understanding of the state of the art in nanobiology and how nanoscale design and multiscale computational modeling can accelerate the discovery and design of nanotechnology-enabled products.”
"How nanodesign is revolutionizing healthcare and medicine" will be the focus of a major seminar to be hosted in Cambridge, Massachusetts, by Accelrys, Inc. (NASDAQ:ACCL), a leading provider of scientific modeling and workflow software solutions. The seminar will provide a deep look at the convergence of nanotechnology and biotechnology and will feature presentations by some of the leading minds in the emerging field of nanotechnology-enabled medicine. The event is free for registrants, and will be held at the Sheraton Commander Hotel in Harvard Square from 10:00 am to 3:00 pm on August 8. Lunch will be provided.
Nanotechnology is poised to make a significant impact on healthcare and medicine, especially in the areas of systems biology, drug delivery and regenerative medicine. The unique physical and spatial properties of nanomaterials allow the engineering of devices and architectures that can perform highly specific tasks as diverse as delivering drugs, destroying tumors, detecting disease markers and restoring visual activity. The free seminar is the first in a series hosted by the Accelrys NanoBiology Initiative, an international collaborative framework drawing on academia, government and industry to address the critical challenges of nanotechnology-enabled pharmaceutical and diagnostic design.
Event details: When: August 8, 2006 Time: 10:00 am - 3:00 pm, lunch provided Where: Sheraton Commander Hotel, Cambridge, Massachusetts Registration: http://www.accelrys.com/info/initiatives/nanobio/seminars.html
"Nanomaterials are fundamentally changing the biotechnology landscape, and our goal at the Accelrys NanoBiology Initiative is to create a new set of computer-based R&D tools capable of anticipating those new needs and adding value every step of the way," said Dr. Deepak Singh, Director of the Accelrys NanoBiology Initiative. "Our seminar in Boston is designed to provide attendees a deep technical and scientific understanding of the state of the art in nanobiology and how nanoscale design and multiscale computational modeling can accelerate the discovery and design of nanotechnology-enabled products."
The highlight of the seminar will be presentations by some of nanobiology's leading thinkers and researchers, including Dr. Rutledge Ellis-Behnke, Research Scientist, Department of Brain and Cognitive Sciences at Massachusetts Institute of Technology, and Dr. Mansoor M. Amiji, Associate Professor of Pharmaceutical Sciences, School of Pharmacy and Associate Director, Nanomedicine Consortium at Northeastern University, as well as an introduction and overview of the NanoBiology Initiative by Dr. Singh.
Following Boston, the seminar series continues through August 15, with events in Chicago (August 9), Seattle (August 10) and San Diego (August 15).
Guided by Scientific Advisory Committee chairman Dr. Leroy Hood (Institute for Systems Biology) and member Dr. Robert Langer (MIT), the Accelrys NanoBiology Initiative is the second of two advanced technology programs Accelrys is currently leading in the area of nanotechnology. The NanoBiology Initiative follows on the success of Accelrys' Nanotechnology Consortium, which was established in 2004 to develop technologies for the design and analysis of advanced materials, and has led to the creation of a robust suite of multiscale tools for Computer Aided NanoDesign(TM) (CAN).
For more information and registration, please see the seminar website at http://www.accelrys.com/info/initiatives/nanobio/seminars.html
Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, modeling, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design, as well as drug discovery and development. SciTegic, Inc., a wholly owned subsidiary of Accelrys, has pioneered a new technology platform called "data pipelining" to process research discovery data with unprecedented flexibility. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/.
This press release contains forward-looking statements. Such statements, including statements relating to the Company's products, including the products' features and potential demand therefore, are subject to risks and uncertainties including, but not limited to, the risks that the products will not be timely or successfully completed, developed or achieve market acceptance, demand relating to these products, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.